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Background:We evaluated current evidence associating thyroid function test result derangements with risk
for mortality in patients with chronic kidney failure treated by long-term dialysis.
Study Design: Systematic review and meta-analysis of cohort studies.
Setting & Population: Dialysis patients.
Selection Criteria for Studies: We searched PubMed, Web of Science, Science Citation Index, Cochrane
Library, and Embase databases from inception through December 2015.
Predictors: Hypothyroidism (thyrotropin level greater than reference range) and low triiodothyronine (T3)
and thyroxine (T4) levels.
Outcomes: All-cause and cardiovascular mortality.
Results: 12 studies involving 14,766 participants (4,450 deaths) were identified. Of those, 6 studies pro-
vided data for cardiovascular mortality (2,772 participants with 327 cardiovascular deaths). Overall, confidence
in the available evidence was moderate. Pooled adjusted HRs for all-cause mortality associated with
hypothyroidism, low T3 level, and low T4 level were 1.24 (95% CI, 1.14-1.34), 1.67 (95% CI, 1.23-2.27),
and 2.40 (95% CI, 1.47-3.93), respectively. Pooled adjusted HRs for cardiovascular mortality associated
with low T3 and T4 levels were 1.84 (95% CI, 1.24-2.74) and 3.06 (95% CI, 1.29-7.24), respectively.
Limitations: Fewer studies reporting on T4 and thyrotropin outcomes.
Conclusions: In patients treated with long-term dialysis, (cardiovascular) mortality is consistently higher in
the presence of thyroid function test result derangements.
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http://dx.doi.org/10.1053/j.ajkd.2016.06.023In patients with chronic kidney disease (CKD), theprogressive loss of kidney function has a negative
impact on the synthesis, excretion, metabolism, and
degradation of thyroid hormones and their metabo-
lites.1,2 As a consequence, thyroid function test result
derangements are common in patients with advanced
stages of CKD, particularly in those with end-stage
renal disease (ESRD).1,3-8 The prevalence of clini-
cally overt and subclinical hypothyroidism increases
with worsening kidney function.4-6 In addition, low
circulating levels of triiodothyronine (T3)
1,3,7,8 and
thyroxine (T4) become increasingly common.
9,10
Uremic conditions that are thought to contribute to
these alterations are multiple, including retention of
iodine and toxins (causing central thyrotropin
[thyroid-stimulating hormone] inhibition, triggering
thyrotropin clearance, and inﬂuencing T3 levels
independently of thyroid function), ineffective protein
binding of T4, reduced T4 levels in tissues, and pri-
marily, impaired conversion of T4 into T3. The latter
is attributed to direct effects of systemic inﬂamma-
tion, elevated cortisol levels, malnutrition, mineral
deﬁciency (eg, selenium resulting in reduced deiodi-
nase activity), metabolic acidosis, commonly used
medications, and additionally in patients with ESRD,y Dis. 2016;-(-):---effects of dialytic procedures (eg, peritoneal efﬂuent
losses).1,3,8,11,12
Observational studies in recent years have attemp-
ted to link these thyroid function test result de-
rangements with the cardiovascular complications and
elevated mortality risk of patients with CKD and
ESRD.9,10,13-23 If associations are causal, this opens
perspectives for thyroid replacement therapy in this
high-risk patient population. Here, we evaluate the
consistency of reported associations between thyroid
function test result derangements and hard end points1
Xu et alin patients undergoing long-term dialysis by means of
a systematic review and meta-analysis.
METHODS
Data Sources and Searches
We systematically searched PubMed and the Web of Science.
Complementary searches and backward and forward citation
tracking were performed through analyses of reference lists, the
Science Citation Index, Cochrane Library, and Embase. The
search was from inception through December 2015. We also
searched unpublished studies and gray literature in a clinical trial
register (www.ClinicalTrials.gov) and conference abstracts for the
major nephrology conferences during 2014 to 2015: American
Society of Nephrology Kidney Week, European Renal Associa-
tion/European Dialysis and Transplant Association Congress, and
International Society of Nephrology Congress. The search string
consisted of 3 parts: (1) the exposure (ie, thyroid disease, hypo-
thyroidism, thyrotropin, T4, and T3), (2) study population (ie,
CKD, ESRD, kidney failure, uremia, hemodialysis [HD], and
peritoneal dialysis [PD]), and (3) outcomes (ie, all-cause mortality,
cardiovascular mortality, survival, fatal, and death). Different
spellings were accounted for, and Medical Subject Headings
(MeSH) were incorporated in the PubMed search (Item S1,
available as online supplementary material).
Exposure, Study Population, and Outcome
The exposure was thyroid function test result derangements,
deﬁned as the following: (1) low T3 level (as measured by total or
free T3, either free T3 level less than the assay-speciﬁc reference
range or free T3 level less than the cutoff value), (2) low T4 level
(by total or free T4, either free T4 level lower than the reference
range or free T4 level less than the cutoff value), and (3) hypo-
thyroidism (thyrotropin level greater than the reference range).
Patient groups with free T3, free T4, and thyrotropin levels within
the normal range or within the highest level category as reported
by each study were used as reference. The study populations
consisted of adults with CKD undergoing long-term dialysis,
either HD or PD.24 Study outcomes were all-cause and/or car-
diovascular mortality during a minimal follow-up of the study
cohort of 3 months.
Inclusion and Exclusion Criteria
Studies were considered for inclusion in the meta-analysis if
they: (1) presented data for measured thyroid function test in
adult (aged $ 18 years) patients with CKD undergoing dialysis
and (2) provided data for all-cause and/or cardiovascular mor-
tality associated with these measurements. Both cohort studies
and case-control studies were eligible, whereas case reports,
case series, and review articles were excluded. We did not
consider studies addressing a combination of these exposures
(eg, hypothyroidism and low free T3 level and low free T4 level
or thyroid function test result derangements with a concurrent
comorbid condition or lifestyle factor). No language restriction
was applied. The languages selected a priori as eligible were
English, Chinese, Swedish, Spanish, French, Dutch, and
German. Studies were eligible only if hazard ratios (HRs) of
thyroid function tests for all-cause or cardiovascular mortality
were reported.
Study Selection
An a priori established study protocol was applied (Item S2).
The search method used to identify all relevant articles was dis-
cussed and developed by the authors and the ﬁnal search string
was approved by all. The initial search was performed by 2 re-
viewers (H.X. and N.B.), who eliminated clearly irrelevant articles
based on the title and abstract as deﬁned by the preset selection2criteria. The ﬁnal selection of articles was made by mutual
consideration of all authors, based on the reporting of all necessary
data and in accordance with the predeﬁned inclusion and exclusion
criteria.
Data Extraction and Quality Assessment
For each article identiﬁed, we extracted information for study
and participant characteristics, thyroid function test description,
and analysis strategy (statistical models and adjustment for
covariates). For each study, crude HRs were extracted (if re-
ported), as well as HRs based on the most fully adjusted Cox
regression models. If different thyroid function test results were
reported in one study (eg, low free T3 or low free T4 levels or
thyrotropin level greater than the reference range), all HRs of the
different exposures were extracted. If several level groups (eg,
tertiles of free T3) were reported, the most extreme comparison,
that is, lowest versus highest level, was considered for the pri-
mary results. We contacted the authors for clariﬁcations of the
protocol and provision of HRs in categorical groupings. Data
analysis used HRs based on the most adjusted (ﬁnal) Cox
regression model in each study. Risk of bias was assessed using
the Newcastle-Ottawa Scale tool.25 Assessment of quality and
generalizability was based on 3 key broad domains considered
fundamental for observational studies: selection of study partic-
ipants, comparability of cohorts on the basis of the design or
analysis, and assessment of outcomes. Study-level risk of bias
was assessed by 2 authors (H.X. and N.B.), and disagreements in
ratings were discussed until consensus. As an overall quality
check and in order to ensure transparent reporting of this sys-
tematic review and meta-analysis, the Meta-analysis of Obser-
vational Studies in Epidemiology (MOOSE) and Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines were followed.
Statistical Analysis
DerSimonian-Laird random-effect meta-analysis and empirical
Bayes metaregression models were performed with STATA,
version 13.0 (StataCorp LP) and were based on the HRs and
standard errors. Values were reported by a forest plot, and un-
certainty about the pooled estimates was quantiﬁed by 95% con-
ﬁdence intervals (CIs). Statistical heterogeneity was assessed by
means of Cochran Q test and I2 test. I2 represents the percentage of
variation attributable to heterogeneity, which was categorized as
low (0%-50%), moderate (51%-75%), or high (.75%).26
We could perform additional empirical Bayes metaregression
models in studies addressing low free T3 levels as the exposure.
These included type of free T3 level ascertainment (less than the
reference range or cutoff value), type of T3 measurements (free or
total T3), type of dialysis therapy (HD or PD), mean follow-up
(12-36 or .36 months), study sample size (,500 or $500 par-
ticipants), confounders in fully adjusted models (with or without
adjustment for malnutrition, inﬂammation, and comorbid condi-
tions), and reported regression models. We also did a sensitivity
analysis to further explore the robustness of results and identify
any study that may have exerted a disproportionate inﬂuence on
the summary effect of low free T3 level on mortality risk. The
presence of small study effects and publication bias was evaluated
by Begg or Egger regression asymmetry analysis.27
RESULTS
Study Selection
We identiﬁed a total of 3,962 publications, of
which 3,479 remained after removing duplicates
(Fig 1). We excluded 3,448 publications based on the
title and abstract because they were unrelated to theAm J Kidney Dis. 2016;-(-):---
Records idenƟfied via PubMed 
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Figure 1. Flow chart for study inclusion; adapted from PRISMA (Preferred Reporting of Systematic Reviews and Meta-analyses).
Thyroid Function and Mortality in Dialysis Patientsstudy of association between thyroid function test
result derangements and mortality. Of the remaining
31 articles, we excluded 10 articles that did not meet
inclusion criteria after full-text screening (1 study was
excluded because of a mixed deﬁnition of exposure,28
1 study included non–dialysis-dependent patients with
CKD,15 and 4 other studies did not present estimates
for a comparison group29-32). We further excluded 9
studies because they investigated cardiovascular sur-
rogates33-41 or cardiovascular disease events,37 but
not mortality risk (detailed in Table S1). Twelve
studies met eligibility criteria and were considered for
meta-analysis.
Study Characteristics
The 12 studies selected for analysis enrolled a total
of 14,766 participants (Table 1), of whom 4,450 died.
Six studies provided data for cardiovascular mortality,
including 2,772 participants and 327 cardiovascular-
related deaths. The studies were from Sweden
(n5 3),9,14,20 South Korea (n 5 2),10,21 Italy
(n5 2),13,18 the United States (n 5 2),16,17 Turkey
(n5 1),19 Germany (n 5 1),22 and Greece (n 5 1).23Am J Kidney Dis. 2016;-(-):---None of them showed an overlap in geographical area
or time.
Mean age ranged from 51 to 66 years, and the
proportion of men ranged from 51% to 74%. Mean
duration of follow-up varied between 12 and 55
months. Two studies analyzed several exposures: one
addressed both low T3 and low T4 levels
9 and the
other addressed low T3 levels and hypothyroidism.
22
Nine studies reported HRs for death associated with
low free T3 levels, 2 in relation to low free T4 levels,
and 3 in relation to hypothyroidism. Among the 9
studies that studied low free T3 levels, 4 deﬁned it by
the reference range,19,21-23 and 5, by tertiles of dis-
tribution,9,13,18 median,20 or receiver operating char-
acteristic–derived14 cutoffs; 6 studies used
measurements of free T3,
13,18-20,22,23 and 3 used
measurements of total T3.
9,14,21 Seven studies
included HD patients, 3 studies included PD patients,
and 2 studies included both HD and PD patients.14,16
Quality Assessment
All studies were population-based cohort studies
and had appropriate methods for thyroid function test3
Table 1. Description and Characteristics of 12 Observational Studies Reporting on the Association Between Thyroid Function Test Derangements and Risk for Mortality
Study Country Cohort N
Mean
Age, y
Male
Sex, %
Exposure
Mortality Events
Mean
F/U, moLow (f) T3 Level
Low (f)
T4 Level Hypothyroidism
a
Zoccali18 (2006) IT HD 200 61 53 ,33rd percentile NA NA All-cause 102 42
Enia13 (2007) IT PD 41 66 63 ,33rd percentile NA NA All-cause 27 34
Carrero14 (2007) SE HD1PD;
euthyroid pts
187 55 63 ,Cutoffs derived
from receiver
operating
characteristics
NA NA All-cause
and CVD
66 (34 CVD) 20
Ozen19 (2011) TR HD;
euthyroid pts
669 54 56 ,Reference range NA NA All-cause
and CVD
165 (94 CVD) 34
Meuwese9 (2012) SE HD 210 62 55 ,66th percentile ,66th
percentile
NA All-cause
and CVD
103 (40 CVD) 38
Meuwese20 (2013) SE PD 84 64 68 ,Median NA NA All-cause 24 32
Koo21 (2013) KR HD 471 57 57 ,Reference range NA NA All-cause
and CVD
49 (22 CVD) 24
Rhee16 (2013) US HD1PD 2,715 63 60 NA NA .Reference range All-cause 917 20
Drechsler22 (2014) DE HD 1,000 66 53 ,Reference range
in euthyroid pts
NA .Reference range,
with normal (f)
T3 and (f) T4
All-cause
and CVD
477 (131 CVD) 48
Jung10 (2014) KR PD 235 51 56 NA ,Median NA All-cause
and CVD
31 (6 CVD) 24
Fragidis23 (2015) GR HD;
euthyroid pts
114 62 74 ,Reference range NA NA All-cause 69 55
Rhee17 (2015) US HD 8,840 65 51 NA NA .Reference range,
with normal (f) T4
All-cause 2,420 12
Note: Euthyroid patients are defined as having both thyrotropin and T4 levels within the reference ranges.
Abbreviations: CVD, cardiovascular disease; DE, Germany; (f) T3, (free) triiodothyronine; (f) T4, (free) thyroxine; F/U, follow-up; GR, Greece; HD, hemodialysis; IT, Italy; KR, Republic of
Korea; NA, not applicable; PD, peritoneal dialysis; pts, patients; SE, Sweden; TR, Turkey; TSH, thyrotropin; US, United States.
aThyrotropin level greater than reference value.
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Thyroid Function and Mortality in Dialysis Patientsmeasurements. Six studies deﬁned exposure cutoffs
with assay reference ranges,16,17,19,21-23 and the others
used cohort-speciﬁc cutoffs (eg, tertiles or median).
Four studies provided a comparison of baseline pa-
tient characteristics according to the analyzed expo-
sures.9,14,16,20 All studies reported mortality follow-up
with cause of death ascertainment from medical re-
cords, describing crude and adjusted HRs (Figs S1
and S2). The covariates used in multivariable
adjustment are detailed in Table S2. Seven studies
considered multivariable adjustment for systemic
inﬂammation biomarkers, which are presumably on
the causal pathway of study exposure and
outcome9,10,13,14,18,21,23; and 2 studies further
adjusted for nutritional status and comorbid
conditions.9,21
Thyroid Function Test Result Derangements and
Death
The pooled adjusted HR for all-cause mortality
associated with low free T3 level was 1.67 (95%NOTE: Weights are from random effects analysis
.
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Figure 2. Forest plot depicts the meta-association between vario
all-cause mortality, using the Dersimonian and Laird random-effec
adjusted reported model. Abbreviations: CI, confidence interval; (f) T3
PD, peritoneal dialysis; TSH, thyrotropin.
Am J Kidney Dis. 2016;-(-):---CI, 1.23-2.27), with moderate heterogeneity
(I2 5 52.1%). The adjusted HR for low free T4 level
was 2.40 (95% CI, 1.47-3.93; I2 5 0%), and for
hypothyroidism, 1.24 (95% CI, 1.14-1.34; I2 5 0%).
These estimates presented low heterogeneity (Fig 2).
Pooled adjusted HRs for cardiovascular mortality
associated with low free T3 (HR, 1.84; 95% CI,
1.24-2.74; I2 5 28.8%) and low free T4 levels (HR,
3.06; 95% CI, 1.29-7.24; I2 5 0%) showed similar
but stronger HRs, with low heterogeneity (Fig 3).
Metaregression models showed similar results but
with broader CIs: the HR for all-cause mortality
associated with low free T3 levels was 1.70 (95%
CI, 1.16-2.50), and with low free T4 levels, 2.40
(95% CI, 0.09-59); the HR for cardiovascular mor-
tality associated with low free T3 levels was 1.84
(95% CI, 1.05-3.21), and with low free T4 levels,
3.06 (95% CI, 0.01-820). Analysis of publication
bias through funnel plots with Begg or Egger tests
could not be performed because of statistical
heterogeneity.422.68 (1.49, 4.84)
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Figure 3. Forest plot depicts the meta-association between various forms of thyroid function test result derangements and risk for
cardiovascular mortality, using the Dersimonian and Laird random-effects model. All hazard ratios (HRs) are based on the most fully
adjusted reported model. Abbreviations: CI, confidence interval; (f) T3, (free) triiodothyronine; (f) T4, (free) thyroxine; HD, hemodialysis;
PD, peritoneal dialysis; TSH, thyrotropin.
Xu et alMetaregression and Sensitivity Analyses of Low T3
Exclusion of single studies from the analysis did
not alter the main ﬁndings (Table S3). Metaregression
analyses suggested that studies deﬁning low free T3
level by cohort-speciﬁc cutoffs (as compared with
studies using reference ranges) and studies using total
T3 measurements (as compared with studies
measuring free T3) tended to have stronger associa-
tions with mortality (Table 2). HD patients with
longer follow-up and larger sample size had lower
HRs as compared with their counterparts. Studies that
considered multivariable adjustment for malnutrition,
inﬂammation, and comorbid conditions showed
higher HRs (Table 2). Due to an insufﬁcient number
of studies, no subgroup analysis for patients by low
T4 levels and hypothyroidism could be performed.
DISCUSSION
In this meta-analysis, risk for all-cause mortality
and cardiovascular-related mortality was consistently
higher in patients undergoing dialysis with thyroid
function test result derangements. This association
persisted throughout a number of sensitivity and
stratiﬁed analyses.
Meta-analysis can be limited by the comprehen-
siveness of searches, the methodological rigor of6included studies, and publication bias, especially
when the meta-analysis includes, as in the current
study, observational studies rather than randomized
controlled trials. We consider the extensive literature
evaluation as a strength of the analysis, but
acknowledge that the number of retrieved articles was
relatively small, reﬂecting the scarcity of literature on
this topic. The pooled HRs are dependent on certain
traits of the published studies—availability, quality,
and methods—and these might be hampered by sta-
tistical heterogeneity and publication bias. We
acknowledge a number of limitations that need to be
considered when interpreting our ﬁndings. First, by
excluding studies that did not report death outcomes,
we cannot rule out the possibility of selection bias.
Second, our analysis plan selected the most adjusted
HR presented in the studies, which despite presenting
the most conservative risk estimation, may result in
outcome reporting bias. Because of statistical het-
erogeneity, funnel plots for detecting publication bias
with the Begg or Egger test were considered not
feasible.42 We attempted to mitigate these biases by
in-depth metaregression analyses, observing alto-
gether a general coherence with the main metaﬁnd-
ings. Because we based our search on English
language2dominated sources, language bias cannot
be excluded. Finally, and regarding the studyAm J Kidney Dis. 2016;-(-):---
Table 2. Metaregression Analyses on Association Between Low Free T3 Level and Mortality Risk
Comparison of Low (f) T3
No. of
Studies
Empirical Bayes Metaregression
Pooled HR (95% CI) P I 2, %a
All-cause mortality
Low (f) T3, defined as , cohort-specific cutoffs
vs , reference range
9 1.75 (0.97-3.14) 0.06 17.8
Total T3 vs (f) T3 measurements 9 1.16 (0.46-2.92) 0.7 54.1
In PD vs HD patients 8 2.57 (0.63-10.60) 0.2 49.9
Studies with follow-up . 36 vs 12-36 mo 9 0.83 (0.35-1.95) 0.6 58.0
Sample size $ 500 vs ,500 patients 9 0.53 (0.33-0.84) 0.02 0
Adjusted for vs not adjusted for malnutrition,
inflammation, and comorbid conditions
9 1.15 (0.37-3.51) 0.8 56.9
Cardiovascular mortality
Low (f) T3, defined as , cohort-specific cutoffs
vs , reference range
5 2.04 (0.66-6.27) 0.1 0
Studies with follow up . 36 vs 12-36 mo 5 0.55 (0.14-2.07) 0.3 13.0
Adjusted for vs not adjusted for malnutrition,
inflammation, and comorbid conditions
5 1.69 (0.42-6.86) 0.3 19.6
Abbreviations: CI, confidence interval; (f) T3, free triiodothyronine; HD, hemodialysis; HR, hazard ratio; PD, peritoneal dialysis.
aI 2 represents the percentage of variation attributable to heterogeneity, typically categorized as low (0%-50%), moderate
(51%-75%), or high (.75%).
Thyroid Function and Mortality in Dialysis Patientsexposure, it has been postulated that commonly used
free T4 assays may be inaccurate in ESRD given the
described alterations in T3 and T4 levels and the
metabolism of thyrotropin.
We found a consistent association between low T3
level and increased risk for death in long-term dialysis
patients. Being based on observational studies, our
data cannot prove causality in the associations.
However, experimental studies show that low T3 level
impairs cardiac tissue oxygen consumption, increases
vascular resistance, and decreases cardiac output.43,44
Observational studies in patients with CKD and those
who progressed to ESRD suggest that low T3 levels
are linked to adverse intermediate surrogates, such as
atherosclerosis,33 vascular calciﬁcation,20,41 arterial
stiffness,33,34 impaired ﬂow-mediated vasodila-
tion,35,40 intravascular volume deﬁcits and abnormal
ventricular conduction,36,37 and impaired cardiac
function,38 which could also explain the associations
reported here. We found overall moderate heteroge-
neity in our estimates. Heterogeneity may be attrib-
uted in part to the use of different T3 cutoffs and
different laboratory methods and measurements of T3
(free vs total). Other potential explanations related to
differences in participant characteristics (eg, study
population, varying follow-up time, sample size, and
adjustment for confounding factors). However, strat-
iﬁed analyses yielded consistent estimates. Compared
with studies that used cohort-based cutoffs (eg, ter-
tiles), those using assay reference range appeared to
have lower mortality risk; this may not be surprising
if CKD (with or without ESRD) per se renders low T3
values and thus cutoffs derived from healthy in-
dividuals may not correctly identify patients at risk.Am J Kidney Dis. 2016;-(-):---The mortality risk estimate associated with low T3
levels was higher in patients with shorter follow-up,
with smaller sample size, and undergoing PD treat-
ment. This collectively may indicate a risk of publi-
cation bias and the scarcity of literature available. We
also report consistency in the associations between
low thyrotropin and low T4 levels, although fewer
studies examined these exposures. In our inclusion
criteria, we considered only baseline thyroid hormone
(T3 and T4) assessments. However, 2 additional re-
ports address longitudinal thyroid hormonal states and
found that persistently low T3 and T4 levels were
associated with 2- to 4-fold higher risk for death in
patients with ESRD,9,10 perhaps offering further
support to our hypothesis.
Our observations are in line with the evidence from
general population studies suggesting that low thyroid
hormone levels, even in subclinical forms, may
negatively affect cardiovascular health and increase
the risk for death.45,46 This evidence includes various,
but not all,47 meta-analyses reporting an overall
increased mortality risk in individuals without CKD
with subclinical thyroid functional disorders, partic-
ularly among those with younger age,48 heart fail-
ure,49 high comorbid condition burden,50 and higher
thyrotropin levels.51 Although the need to treat these
subclinical disorders is recommended in some
guidelines and consensus papers as a strategy to
reduce cardiovascular risk,52,53 there is a paucity of
interventional data in patients with CKD and those
who progressed to ESRD. An early interventional
study showed that intake of physiologic doses of T3
(50 mg/d) decreased thyrotropin levels and resulted in
a borderline negative nitrogen balance (increased7
Xu et alprotein catabolism) in patients with ESRD.54 This
may be the natural consequence of restoring thyroid
function and in our opinion may be easily counter-
acted by increasing protein intake. Outside
nephrology, short-term T3 replacement therapy
greatly improved the neuroendocrine proﬁle and
ventricular performance in patients with heart failure
with low T3 syndrome.
55 Before trials are conducted,
other indirect approaches that may serve as proofs of
concept include correcting acidosis,56,57 oxidative
stress,58 or selenium deﬁciency.59 In a placebo-
controlled study of 30 euthyroid patients undergoing
HD, exogenous T4 administration over 3 months
reduced lipoprotein(a) and total and low-density li-
poprotein cholesterol levels, without evidence of
thyrotoxicosis.60 However, in a recent large obser-
vational study of patients with ESRD, hypothyroid
patients receiving exogenous thyroid hormones were
at the same risk for death compared with those
without medication.16
In summary, all-cause and cardiovascular mortality
was found to be consistently higher for long-term
dialysis patients with thyroid function test result de-
rangements. These derangements may represent an
under-recognized risk factor, with a biologically
plausible link to the poor clinical outcomes of this
population. The observed associations of this meta-
analysis raise the question of whether it would be
cost-effective to screen for thyroid function among
patients with ESRD and whether patients with sub-
clinical signs of hypothyroidism would beneﬁt from
corrections of thyroid hormone deﬁciencies to the
normal range.
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